Research library

1,742 reports · By date added

Citi: Why are Sinopec’s refining margins resilient? Citi points to crude procurement discounts and easing fuel-price adjustment pressure

The discount on China’s imported crude relative to South Korea’s has widened, while the increase in costs not passed through to domestic gasoline and diesel prices has narrowed from its earlier level. Citi therefore expects Sinopec’s core refining gross margin to remain at 6–8 dollars per barrel in the second half of 2026, although higher freight costs and weak demand remain constraints.

Citi: Risk aversion resembles a French fiscal shock, while AI hedging increases

Recent cross-asset performance most closely resembles concerns over French public finances, but worries about AI financing are growing. Citi has added a USD/JPY volatility hedge and gone long UK and Spanish government bonds relative to French bonds; despite elevated credit stress, sector concentration keeps it preferring equities over credit.

Citi: Markets begin pricing in a slowdown in AI investment as Fed rate path faces uncertainty

Citi interprets falling stock prices, widening credit spreads and declining Treasury yields as signs that markets are assigning a higher probability to a slowdown in AI spending. The bank still expects a rate hike in December, but the buffers provided by consumption and housing are weakening, and further stock market declines could change the policy direction.

Citi: Embraer’s orders and deliveries grow together as Citi sees defense upside

Embraer’s third-quarter backlog rose to 35.7 billion dollars, with new orders exceeding revenue in every business segment; deliveries in the first three quarters also ran ahead of historical levels. Citi rates the stock Buy and sees particularly strong upside in defense, but realizing that value depends on new selections becoming orders, order pricing and delivery execution.

Goldman Sachs: GenFleet’s GFH276 debuts: Pancreatic cancer response rate exceeds Goldman Sachs’ expectations; subsequent dose selection is key

GFH276 achieved an objective response rate of 41% in pancreatic cancer patients treated predominantly in the third-line setting or later, exceeding Goldman Sachs’ previously established threshold. Efficacy and tolerability support further exploration, but higher doses showed no clear efficacy benefit, and skin toxicity and long-term tolerability will influence subsequent dose selection.

Goldman Sachs: Telecom sector September tracker: 5G construction rebounds month on month, while optical cable exports outperform overall production

China added 59 thousand 5G base stations in September, but Goldman Sachs still expects full-year additions to be lower than in 2025. Optical cable export volume rose 52% year on year, diverging from a 22% decline in domestic output; base station exports continued to contract, with the improvement in overseas demand concentrated in certain segments.

Morgan Stanley: Shennan Circuits’ third-quarter profit beats expectations: AI share rises to sixty percent, ABF moves toward quarterly profitability

Net profit in the third quarter of 2026 was 18% above the market consensus, driven mainly by a higher share of AI PCBs, rising capacity utilization and narrower ABF losses. Optical module PCB upgrades and packaging substrate capacity expansion offer room for further growth, but the ramp-up of 1.6T products and ABF profitability each have their own timing thresholds. Morgan Stanley maintains its Equal-weight rating.

Goldman Sachs: Novartis’s remibrutinib falls short of investor efficacy thresholds: How much sales can its safety advantage support?

Goldman Sachs believes remibrutinib’s multiple sclerosis data fell short of investor expectations and that its better liver safety is insufficient to drive rapid replacement of existing therapies. The company has set a peak sales target of more than 8 billion US dollars across all indications, but evidence on switching treatments and the pace of physician adoption remain key constraints.

J.P. Morgan: North American metals earnings diverge: steelmakers benefit from delayed price increases, aluminum processors struggle with execution, and gold miners face greater cost scrutiny

JPMorgan believes steelmakers can still benefit from price pass-through in the fourth quarter, although leading indicators for construction are weakening. Demand and earnings performance vary across aluminum processors, while gold equities require a comparison of costs, valuations and the timing of growth delivery.

Morgan Stanley: China National Building Material narrows third-quarter loss: How much improvement can higher cement prices bring?

China National Building Material’s third-quarter net loss narrowed to 67 million yuan, but basic building materials remained weighed down by volumes and prices. Morgan Stanley expects cement price stabilization to drive a modest improvement in the fourth quarter, while new materials such as fiberglass continue to support growth. It maintains an Equal-weight rating.